argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of argenex SE (NASDAQ:ARGX) have earned a consensus rating of “Moderate Buy” from the twenty-four brokerages that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $1,016.2222.

A number of research firms have recently issued reports on ARGX. Royal Bank Of Canada dropped their price target on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Robert W. Baird upped their price target on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Wedbush restated an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research report on Monday, March 9th. Finally, Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th.

Institutional Investors Weigh In On argenex

A number of large investors have recently made changes to their positions in ARGX. AQR Capital Management LLC lifted its holdings in argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after acquiring an additional 122 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares during the last quarter. Focus Partners Wealth lifted its holdings in argenex by 22.3% in the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after acquiring an additional 50 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Trading Down 0.1%

NASDAQ:ARGX opened at $799.65 on Friday. argenex has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a 50 day moving average of $766.43 and a two-hundred day moving average of $814.62. The firm has a market cap of $49.48 billion, a P/E ratio of 40.97, a price-to-earnings-growth ratio of 1.34 and a beta of 0.46.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Saturday, February 14th. The company reported $8.02 earnings per share (EPS) for the quarter. argenex had a return on equity of 38.51% and a net margin of 30.42%. On average, research analysts forecast that argenex will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.